• Je něco špatně v tomto záznamu ?

External validation of the DIAFORA system to predict lower-extremity amputations in a prospective Danish cohort

J. Røikjer, M. Monteiro-Soares, D. Walton, E. Iacopi, J. Jirkovska, M. Edmonds, A. Trocha, W. Jeffocate, S. Bus, Diabetic Foot Study Group (DFSG) prevention of the first ulcer research group

. 2025 ; 42 (1) : e15443. [pub] 20240928

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, validační studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25002917

AIM: A diabetes-related foot ulcer (DFU) is a major risk factor for lower-extremity amputation (LEA). To help clinicians predict the risk of LEA in people with DFU, the Diabetic Foot Risk Assessment (DIAFORA) system was developed but has never been externally validated. METHODS: In this study, 317 people presenting with a new DFU were included. At baseline, participants were grouped into three groups based on their DIAFORA score: low-risk (<15), medium-risk (15-25), and high-risk (>25). Participants were followed until healing, LEA, death, or at least 3 months. Discriminative accuracy was evaluated using sensitivity, specificity, likelihood ratios (LRs) and the area under the curve (AUC). RESULTS: All 317 participants completed at least 3 months of follow-up for a median duration of 146 days, during which 12.6% underwent minor amputation and 2.5% major amputation. People in the low- and medium-risk categories had major amputation rates of 0.9% and 2.1%, respectively, and negative LR of major LEA of 0.10 and 0.38, respectively, while the people in the high-risk category had an amputation rate of 25.0% and a positive LR of 12.9. The DIAFORA risk groups had a sensitivity of 75.0% and a specificity of 65.7%, with a corresponding AUC of 0.78 (95% CI 0.68-0.87) for the prediction of major LEA. CONCLUSION: The DIAFORA score is a useful tool for risk stratification of people presenting with a newly occurred DFU, with the external validation presenting results similar to those presented in the original study. The DIAFORA score may guide clinicians towards more individualized DFU treatment regimens.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002917
003      
CZ-PrNML
005      
20250206103938.0
007      
ta
008      
250121s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/dme.15443 $2 doi
035    __
$a (PubMed)39340796
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Røikjer, Johan $u Steno Diabetes Center North Denmark, Aalborg University Hospital, Aalborg, Denmark $1 https://orcid.org/0000000245781328
245    10
$a External validation of the DIAFORA system to predict lower-extremity amputations in a prospective Danish cohort / $c J. Røikjer, M. Monteiro-Soares, D. Walton, E. Iacopi, J. Jirkovska, M. Edmonds, A. Trocha, W. Jeffocate, S. Bus, Diabetic Foot Study Group (DFSG) prevention of the first ulcer research group
520    9_
$a AIM: A diabetes-related foot ulcer (DFU) is a major risk factor for lower-extremity amputation (LEA). To help clinicians predict the risk of LEA in people with DFU, the Diabetic Foot Risk Assessment (DIAFORA) system was developed but has never been externally validated. METHODS: In this study, 317 people presenting with a new DFU were included. At baseline, participants were grouped into three groups based on their DIAFORA score: low-risk (<15), medium-risk (15-25), and high-risk (>25). Participants were followed until healing, LEA, death, or at least 3 months. Discriminative accuracy was evaluated using sensitivity, specificity, likelihood ratios (LRs) and the area under the curve (AUC). RESULTS: All 317 participants completed at least 3 months of follow-up for a median duration of 146 days, during which 12.6% underwent minor amputation and 2.5% major amputation. People in the low- and medium-risk categories had major amputation rates of 0.9% and 2.1%, respectively, and negative LR of major LEA of 0.10 and 0.38, respectively, while the people in the high-risk category had an amputation rate of 25.0% and a positive LR of 12.9. The DIAFORA risk groups had a sensitivity of 75.0% and a specificity of 65.7%, with a corresponding AUC of 0.78 (95% CI 0.68-0.87) for the prediction of major LEA. CONCLUSION: The DIAFORA score is a useful tool for risk stratification of people presenting with a newly occurred DFU, with the external validation presenting results similar to those presented in the original study. The DIAFORA score may guide clinicians towards more individualized DFU treatment regimens.
650    _2
$a lidé $7 D006801
650    12
$a amputace $x statistika a číselné údaje $7 D000671
650    12
$a diabetická noha $x chirurgie $x epidemiologie $7 D017719
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    _2
$a prospektivní studie $7 D011446
650    _2
$a hodnocení rizik $x metody $7 D018570
650    _2
$a dolní končetina $x chirurgie $7 D035002
650    _2
$a rizikové faktory $7 D012307
650    _2
$a kohortové studie $7 D015331
650    _2
$a senzitivita a specificita $7 D012680
650    _2
$a prediktivní hodnota testů $7 D011237
651    _2
$a Dánsko $x epidemiologie $7 D003718
655    _2
$a časopisecké články $7 D016428
655    _2
$a validační studie $7 D023361
700    1_
$a Monteiro-Soares, Matilde $u Portuguese Red Cross School of Health-Lisbon, Lisbon, Portugal $u MEDCIDS-Departamento de Medicina da Comunidade Informação e Decisão em Saúde, Faculty of Medicine of the University of Porto, Porto, Portugal $u RISE@CINTESIS, Faculty of Medicine Oporto University, Porto, Portugal $1 https://orcid.org/0000000245862910
700    1_
$a Walton, Daina $u Lewisham and Greenwich NHS Trust, Foot Health Service, London, UK $u Department of Biosciences and Medicine, University of Surrey, Surrey, UK $1 https://orcid.org/000000020555071X
700    1_
$a Iacopi, Elisabetta $u Department of Medicine and Surgery Endocrine-Metabolic and of Transplantation, University of Pisa, Italy $1 https://orcid.org/0000000290079378
700    1_
$a Jirkovska, Jarmila $u Medical Department of the First Faculty of Medicine and Military University Hospital Prague, Diabetes Center and Foot Clinic, Czech Republic
700    1_
$a Edmonds, Michael $u Diabetic Foot Clinic and Diabetic Department, King's College Hospital, London, UK $u Department of Diabetes, Faculty of Life Sciences and Medicine, King's College, Strand, London, UK
700    1_
$a Trocha, Anna $u Clinical Diabetes Center, Elisabeth Hospital Essen, Essen, Germany $1 https://orcid.org/0009000164715043
700    1_
$a Jeffocate, William $u Retired Physician, Nottingham University Hospitals NHS Trust, UK $1 https://orcid.org/0000000217447576
700    1_
$a Bus, Sicco $u Amsterdam UMC, University of Amsterdam, Department of Rehabilitation Medicine, Amsterdam, The Netherlands $u Amsterdam Movement Sciences, Rehabilitation and Development program, Amsterdam, The Netherlands $1 https://orcid.org/0000000283579163
710    2_
$a Diabetic Foot Study Group (DFSG) prevention of the first ulcer research group
773    0_
$w MED00001389 $t Diabetic medicine $x 1464-5491 $g Roč. 42, č. 1 (2025), s. e15443
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39340796 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206103934 $b ABA008
999    __
$a ok $b bmc $g 2262982 $s 1238924
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 42 $c 1 $d e15443 $e 20240928 $i 1464-5491 $m Diabetic medicine $n Diabet Med $x MED00001389
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace